Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials

Core Insights - Eli Lilly and Company announced a $4.5 billion investment to establish the Lilly Medicine Foundry, a facility aimed at advanced manufacturing and drug development, set to open in late 2027 [1][2] - This investment will increase Lilly's total capital commitment in the United States to over $23 billion since 2020, with more than $13 billion specifically in Indiana [1][3] Investment and Economic Impact - The Medicine Foundry will enhance Lilly's ability to research and manufacture medicines for clinical trials, optimizing processes and increasing capacity while reducing costs and environmental impact [2][3] - The facility is expected to create 400 full-time jobs for skilled workers, contributing to Indiana's economy and solidifying the state's role as a hub for science and technology [3] Technological Advancements - The Medicine Foundry will support the production of various molecular therapies, including small molecules, biologics, and nucleic acid therapies, with new technologies developed there being transferred to other manufacturing sites [2][3] Previous Commitments - Lilly's investment in Lebanon includes a $2.1 billion commitment in May 2022 for two new manufacturing sites, an additional $1.6 billion in April 2023, and a $5.3 billion investment in May 2024 for active pharmaceutical ingredients, marking the largest single investment in this area in U.S. history [3]